M ultiple risk factor intervention is essential in order to prevent cardiovascular (CV) disease in patients with diabetes. Therefore, to reduce atherothrombotic events, an ideal oral anti-diabetic agent should be able to modulate most, and preferably all, cardiovascular risk factors associated with diabetes.
Introduction
Diabetes incurs microvascular and macrovascular complications, resulting in a high degree of morbidity and a 30% decrease in life expectancy. 1, 2 Large-vessel atherosclerosis, unlike microvascular disease, can precede the development of diabetes, suggesting that atherosclerosis is not a complication of diabetes but rather a co-existing condition. Furthermore, patients with diabetes and with no previous history of cardiovascular disease (CVD) have a risk of myocardial infarction (MI) similar to the risk among patients without the disease who have had previous cardiac events. 2 Therefore, diabetes and CVD are often regarded as the same entity, [3] [4] [5] forming the basis for the 'common soil' hypothesis, which postulates that type 2 diabetes mellitus (T2DM) and CVD share common genetic and environmental antecedents, and that the development of these conditions is a consequence of the clustering of risk factors. These risk factors can be divided into traditional (e.g. abdominal obesity, hyperglycaemia, dyslipidaemia and hypertension) and nontraditional (e.g. low-grade inflammation, hypercoagulation and hypofibrinolysis) factors (figure 1). It is thought that insulin resistance underpins this clustering of risk and together, the collection of traditional risk factors has been defined, using different criteria, as the metabolic syndrome. 3, 4, 6 Although the existence of such a syndrome has recently been questioned, there is little doubt that CVD is a condition caused by cumulative aggregation of risk factors and pre- vention is therefore only possible by collective modulation. 4, 7, 8 In support of this, the Steno-2 trial has shown that aggressive intervention and treatment of multiple risk factors in individuals with diabetes reduces future cardiovascular events, a finding that has been emphasised in a number of other studies. 9, 10 It is clear that CVD prevention in diabetes requires a complex management plan directed at modulating multiple risk factors. In this review we discuss the effects of different oral antidiabetic agents (OADs) on cardiovascular risk factors and their role in the prevention of CVD in patients with diabetes.
Pathogenesis of atherosclerosis
One of the earliest abnormalities in the atherosclerotic process is endothelial dysfunction. 11, 12 Endothelial cells (ECs) are major contributors to the control of vascular tone, inflammation and thrombosis, through the production of nitric oxide (NO), inflammatory cytokines, pro-thrombotic agents and anticoagulant factors. In a healthy environment, there is a balanced secretion of these products which maintains the integrity of the luminal surface, ensuring protection of the vessel wall and providing adaptive laminar blood flow.
Endothelial damage disrupts this balance and initiates a number of events that play a pivotal role in the initiation and progression of the atherosclerotic process. Diseased ECs express adhesion molecules, resulting in binding of inflammatory cells with subsequent migration into the vessel wall, together with low-density lipoprotein cholesterol (LDL). The latter is transformed in the vessel wall into oxidised LDL (ox-LDL), a highly atherogenic molecule, which is taken up by migrating monocytes to form foam cells. The formation of ox-LDL is increased in diabetes due to excessive production of reactive oxygen species (ROS) and impairment of the scavenging capacity of the antioxidant systems. 13 Subsequent accumulation of foam cells leads to the formation of the fatty streak, which is the earliest visible abnormality in atherosclerosis, seen even in children.
Intensification of the inflammatory process in the vessel wall leads to expansion of the fatty streak, forming a lipid core covered by a thin cap which is strengthened and stabilised by the production of collagen. However, cytokines and macrophage-derived matrix metalloproteinases (MMPs) can degrade this collagen, rendering the cap weak and prone to rupture. 14 Once the plaque ruptures, this permits contact between the procoagulant lipid core and blood, initiating thrombus formation. In addition to local vessel inflammation, atherosclerosis is associated with a generalised inflammatory reaction. Plasma levels of interleukin (IL)-1, IL-6, tumour necrosis factor-α (TNFα), C-reactive protein (CRP) and complement factors are increased in atherosclerosis, 15 and CRP levels are good indicators of future thrombotic events. 16 In addition to facilitating the development of atherosclerosis, inflammation plays an important role in thrombotic complications. Inflammatory cell-derived cytokines degrade collagen around the fibrous cap, making it susceptible to rupture. Furthermore, cytokines stimulate procoagulant and inhibit fibrinolytic protein production by ECs, thereby creating a pro-thrombotic and vasoconstrictive environment. 12 Cluster of cardiovascular risk factors in patients with type 2 diabetes Traditional cardiovascular risk factors Hyperglycaemia and insulin resistance, central obesity, dyslipidaemia, hypertension and microalbuminuria represent the traditional risk factors for CVD. Insulin resistance has been long regarded as an important element of the cluster of cardiovascular risk factors, which is considered by some as key to the development of the metabolic syndrome. 6, 17, 18 The majority of T2DM patients display insulin resistance, 19 manifest by decreased tissue sensitivity to the action of insulin. A genetic predisposition to insulin resistance is suggested by the observation of decreased insulin sensitivity in a greater proportion of relatives of patients with T2DM. 20 Insulin resistance is associated with atherogenic changes in risk factors, including an adverse lipid profile and a prothrombotic milieu, predisposing to increased risk of developing CVD. 6, 19 Furthermore, hyperglycaemia is a risk factor for CVD, [21] [22] [23] contributing to endothelial dysfunction and oxidative stress, which are both central to the development of atherosclerosis. 24 However, lowering of HbA 1C has only a modest effect on cardiovascular risk reduction in the T2DM patient, 25 indicating that treatment of hyperglycaemia per se, without addressing other risk factors, has only a minor effect on cardiovascular risk reduction. Nevertheless, improvement of glycaemic control remains important as it ameliorates microvascular disease and reduces longer-term cardiovascular risk.
Dyslipidaemia
Many studies have confirmed that an abnormal lipid profile is a risk factor for CVD. [26] [27] [28] [29] [30] Patients with diabetes exhibit an atherogenic lipid profile characterised by elevated triglyceride (TG) and low levels of high-density lipoprotein cholesterol (HDL). LDL levels are not significantly different in subjects with diabetes compared with the general population but there is an increased proportion of small, dense atherogenic LDL particles among patients with diabetes. Several studies have shown that manipulation of the lipid profile reduces cardiovascular risk in both people with diabetes and those individuals without the disease. Most studies have focused on reducing LDL levels; 30, 31 the targets have frequently been revised with recent guidelines from the Joint British Societies (JBS-2) suggesting target LDL levels of < 2.0 mmol/L in patients with diabetes. 32 Studies on TG modulation by fibrate treatment have also shown some reduction in cardiovascular risk but there are fewer data on these compared to statins. [33] [34] [35] Although epidemiological data show convincingly that low HDL is an independent risk factor for CVD, 36, 37 there is a general lack of outcome studies that have specifically investigated the effect of modulating HDL levels on future cardiovascular events. However, it should be noted that the beneficial cardiovascular effects of fibrate treatment in the Department of Veterans Affairs High-Density Lipoprotein Intervention (VA-HIT) study may have been partially due to an increase in HDL levels. 33 Hypertension Hypertension is common in patients with diabetes and is a major risk factor for the development of CVD. [38] [39] [40] [41] [42] Tight blood pressure (BP) control reduces cardiovascular risk in these patients, and recent guidelines stress the importance of BP control, particularly in those with multiple risk factors. 32, 43 Microalbuminuria Patients with diabetes are screened for microalbuminuria, to detect incipient renal disease. 44, 45 Microalbuminuria is also associated with increased risk of cardiovascular disease in patients with and without diabetes. [46] [47] [48] [49] This has led to the widely held view that microalbuminuria is an indirect marker of endothelial dysfunction and is indicative of widespread vascular damage. 50 In summary, microalbuminuria seems to have a dual significance as it is not only a marker of early renal impairment but also an indicator of vascular dysfunction.
Non-traditional cardiovascular risk factors Inflammation
Inflammation has a central role in the initiation and progression of the atherothrombotic process. A link between insulin resistance and inflammation was suggested in 1993, following the demonstration of high TNFα expression in adipocytes from obese mice and rats, and that administration of soluble TNFα receptors ameliorated insulin resistance in these animals. 51 Human work has shown increased adipose tissue expression of TNFα and elevated plasma concentrations of the protein in obese individuals, which can be reduced by weight loss. 52, 53 Plasma levels of other inflammatory molecules, including IL-6, IL-18, CRP and adhesion molecules, are elevated in insulin resistance, confirming the association of this condition with a generalised inflammatory state. [54] [55] [56] [57] [58] Diabetes is also associated with increased MMP levels, thereby facilitating plaque rupture with subsequent initiation of thrombus formation. 59 In addition, insulin resistance is associated with increased oxidative stress, resulting in ox-LDL and atheroma formation. [60] [61] [62] Just over a decade ago, two adipocyte-derived molecules, leptin (a satiety factor which regulates appetite) and adiponectin (which appears to have an important role in regulating tissue sensitivity to insulin), were identified. There is now evidence that these hormones may act to link inflammation, insulin resistance and atherosclerosis. Leptin, which is increased in insulin resistance, may play a direct role in atherosclerosis by augmenting oxidative stress and inflammation in the vessel wall, 63 as well as inducing a generalised inflammatory response by stimulating IL-6 production by adipose tissue. 64 A recent study has shown a good correlation between leptin levels and a number of risk factors, including body mass index (BMI), waist hip ratio (WHR), BP and CRP. 65 In contrast, adiponectin, which is suppressed in insulin resistance, normally downregulates adhesion molecule expression on ECs, and inhibits foam cell formation and vascular smooth muscle cell migration. 66 The importance of these hormones in atherothrombosis has been highlighted by the demonstration of a positive correlation between leptin levels and risk of MI and a negative correlation between adiponectin levels and MI risk. 67, 68 Hypercoagulation and hypofibrinolysis Intravascular clot formation is the result of a complex interaction between platelets and clotting factors. Plaque rupture results in a break in the inner lining of the vessel wall, which brings plasma into contact with tissue factor-bearing cells and causes the platelets to adhere to the site of injury. Interactions between activated platelets and coagulation factors result in activation of the coagulation cascade, culminating in the formation of a fibrin clot (figure 2). Clot lysis occurs as a result of plasmin formation from plasminogen, which is facilitated by tissue plasminogen activator (tPA) and inhibited by plasminogen activator inhibitor-1 (PAI-1). 12 A defence mechanism against thrombosis occurs via natural anticoagulants, including protein C, tissue factor pathway inhibitor and thrombomodulin. 12 Obesity and insulin resistance are associated with increased platelet activation, predisposing the patient to thrombotic events. 12 Diabetes and insulin resistance can also modulate plasma levels and activity of a number of clotting factors (including tissue factor, fibrinogen and factor VII, in addition to molecules involved in clot lysis including tPA and PAI-1), creating a pro-thrombotic environment. 12 Also, diabetes can directly affect clot structure, probably through increased glycation of clotting factors, resulting in clots that are resistant to lysis, which may predispose the patient to more severe CVD. 12 In summary, diabetes and insulin resistance promote inflammatory changes in the vessel wall, increase oxidative stress and create a state of generalised inflammation, thereby predisposing to atherosclerosis. In addition, diabetes and REVIEW Figure 2 . Plaque rupture in an atherosclerotic vessel causes platelet aggregation and activation of the coagulation system, resulting in the formation of a fibrin clot. This causes activation of the fibrinolytic system and production of plasmin, a process mediated by tissue plasminogen activator (tPA), resulting in degradation of the fibrin clot. One of the powerful inhibitors of the fibrinolytic system is plasminogen activator inhibitor (PAI)-1, and high plasma levels of this protein are associated with impaired fibrinolysis and increased risk of cardiovascular disease Plaque rupture
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Cardiovascular effects of commonly used oral antidiabetic agents (OADs)
It is clear that management of hyperglycaemia alone only offers partial protection from the macrovascular complications of diabetes, and that clustering of risk factors needs effective management. Therefore, to prevent cardiovascular disease in individuals with diabetes, OADs should ideally lower blood glucose and address the cardiovascular risk cluster.
Metformin
Mode of action
Metformin has a number of effects, some insulin-dependent and others not, which collectively lower plasma glucose in patients with diabetes; these effects are comprehensively reviewed elsewhere. 69 Briefly, metformin suppresses gluconeogenesis, reduces glycogenolysis, increases glucose turnover and enhances insulin-stimulated glucose uptake in skeletal muscle. In addition, metformin ameliorates insulin resistance, which is a key factor in the development of T2DM.
Effects of metformin on traditional risk factors By reducing insulin resistance and exerting an anti-hyperglycaemic effect without causing weight gain, 69, 70 and following the United Kingdom Prospective Diabetes Study (UKPDS) data in relation to cardioprotection, 71 metformin has become first choice OAD in overweight patients with diabetes. 72 A meta-analysis of 19 randomised, controlled clinical trials (RCTs) has shown no effect of metformin on systolic BP (SBP) or diastolic BP (DBP). 73 The addition of metformin to insulintreated T2DM subjects has also failed to show any effect on BP. 74 More recent analysis of 29 trials and a new RCT has shown a small positive effect of metformin on DBP. 72, 75 Metformin probably has, at most, a minor BP-lowering effect, which may be related to reduction in insulin resistance, decreased weight and improvement in endothelial dysfunction. 70 On analysis of 37 trials, metformin significantly reduced TG levels, an effect related to improvement in diabetes control. 76 A meta-analysis of 24 trials has demonstrated that metformin is associated with a modest reduction in LDL, which is independent of glycaemic control. However, metformin had no effect on HDL when the results of 29 trials were collectively analysed. 73 A separate review of 10 clinical studies concluded that high doses of metformin result in reduction in total cholesterol (TC), with a non-significant effect on LDL and HDL. 76 An analysis of 29 trials comparing the effect of metformin monotherapy with other OAD treatment has shown that metformin was more effective than sulphonylureas in reducing LDL, whilst having a favourable effect on weight. 72 Metformin, used as monotherapy or as combination treatment, does not seem to have an effect on microalbuminuria in subjects with diabetes. 77 The effects of metformin on traditional risk factors are summarised in table 1.
Effects of metformin on non-traditional risk factors
Metformin is associated with a reduction in both oxidative stress and plasma CRP levels. [78] [79] [80] However, it has a differential effect on plasma TNF as it increases levels in lean subjects without having an effect in obese individuals. 81 Despite improvement in insulin sensitivity, metformin does not have REVIEW Blood pressure Urinary ACR Key: = no effect; = reduced; = increased; ? = unknown; ~ = approximately (mean of several studies cited herein); HbA 1C = glycosylated haemoglobin; TG = triglycerides; TC = total cholesterol; LDL = low-density lipoprotein cholesterol; HDL = high-density lipoprotein cholesterol; ACR = albumin-creatinine ratio; SUs = sulphonylureas; TZDs = thiazolidinediones; AGIs = α-glucosidase inhibitors an effect on circulating adiponectin levels. 82, 83 Metformin inhibits EC expression of adhesion molecules and restores NO-dependent EC function, indicating an improvement in endothelial dysfunction. 70, 84 Metformin affects the coagulation system by inhibiting platelet aggregation and reducing levels of fibrinogen, factor VII (FVII) and PAI-1, thereby lowering thrombotic risk. Clots formed in the presence of metformin lyse more quickly, which may be related to direct modulation of clot structure by this agent. 85, 86 The antiinflammatory and anti-thrombotic effects of metformin, which are summarised in table 2, may be explained by improvement in insulin resistance and restoration of endothelial function. 87 
Sulphonylureas
Mode of action Agents in the sulphonylurea (SU) group target the adenosine triphosphate (ATP)-dependent potassium channel (KATP), which is composed of two proteins, SUR and Kir6.2. The structure of the receptor varies in different sites: SUR1/Kir6.2 is found in pancreatic beta-cells, SUR2A/Kir6.2 in striated muscle (including the heart) and SUR2B/Kir6.2 in smooth muscle. Binding of the SU to its receptor in the pancreas results in closure of the SUR1/Kir6.2 channel, stimulating insulin secretion by pancreatic beta-cells. 88, 89 The KATP channel in the heart is of major interest as it is involved in adaptation to ischaemia: it opens in ischaemic conditions, resulting in coronary vascular dilatation. Although SUR2A/Kir6.2 has no SU binding site, it has a benzamido binding site. Therefore treatment with SUs which have a benzamido group, during acute cardiac ischaemia may have a deleterious effect on the heart by interfering with KATP channel opening. 88, 89 Effect of sulphonylureas on traditional risk factors Although these agents are effective at reducing blood glucose, their use is associated with weight gain, an undesirable side effect. 90 Some studies with SUs have shown that these agents may improve the lipid profile in patients with dia-betes but the changes were modest and generally did not reach statistical significance. 76 Studies with meglitinide insulin secretagogues (nateglinide and repaglinide) have been inconsistent.
A recent randomised, double-blind study compared gliclazide with pioglitazone monotherapy over 52 weeks in 1,270 T2DM patients with HbA 1C levels of 7.5-11%. Gliclazide was associated with a 5% reduction of LDL levels compared with a 3% reduction in patients on pioglitazone treatment, but the latter was associated with a significantly higher rise in HDL (20% and 6% for pioglitazone and gliclazide, respectively) resulting in a bigger fall in the TC:HDL ratio. 91 TG levels fell with both treatments, which may have been related to improvement in diabetes control (17% and 14% for pioglitazone and gliclazide, respectively). 91 Gliclazide used in combination therapy with metformin in 313 T2DM patients had only a minor effect on TG and LDL (7% and 3% reduction, respectively), without affecting HDL levels. 92 The reduction in TC:HDL ratio was 20% with metformin/gliclazide treatment compared with 53% in patients treated with metformin/pioglitazone. It seems that the effect of sulphonylureas on the lipid profile is relatively small and the beneficial effects seen in some studies are possibly consequent to improvements in glycaemic control.
Treatment with glyburide has been associated with a small increase in SBP over 52 weeks, with no change in DBP. 93 Using pooled data comparing the cardiovascular effect of pioglitazone, metformin and gliclazide from four double-blind randomised trials, each conducted over a oneyear period and involving more than 3,700 T2DM patients, gliclazide treatment was associated with a minor reduction in both SBP and DBP (-0.7 mmHg and -0.6 mmHg, respectively), an effect that was smaller than that observed with pioglitazone (-1.6 mmHg and -1.4 mmHg) or metformin (-1.5 mmHg and -1.2 mmHg). Furthermore, patients on gliclazide had an increased incidence of newly diagnosed hypertension or worsening of existing hypertension compared with patients in the metformin and pioglitazone groups. 75 Key: = no effect; = reduced; = increased; ? = unknown; ~ = approximately (mean of several studies cited herein); HbA 1C = glycosylated haemoglobin; TG = triglycerides; TC = total cholesterol; LDL = low-density lipoprotein cholesterol; HDL = high-density lipoprotein cholesterol; ACR = albumin-creatinine ratio; SUs = sulphonylureas; TZDs = thiazolidinediones; AGIs = α-glucosidase inhibitors Two small studies have shown no effect of glibenclamide on urinary albumin excretion, 94, 95 although another small study of poorly controlled T2DM patients with microalbuminuria reported that gliclazide reduced the urinary albumin creatinine ratio (UACR). 96 This latter finding has been confirmed in a much larger study involving more than 600 T2DM patients, which reported that gliclazide monotherapy was associated with a 17% reduction in UACR. 77 In that study, the renoprotective effect was not apparent with combination therapy. 77 In fact, combination therapy with SUs may worsen microalbuminuria: in a study involving 313 T2DM patients, gliclazide added to existing metformin treatment was associated with a 6% increase in ACR after 52 weeks of treatment. 92 The effects of SUs on traditional risk factors are summarised in table 1.
REVIEW
Effects of sulphonylureas on non-traditional risk factors
In a small study of 22 poorly controlled T2DM patients, treatment with glibenclamide had no effect on plasma CRP, IL-6 or TNFα levels. 95 In a larger study of 84 T2DM patients with relatively good control of their diabetes (HbA 1C 7.4%), glimepiride treatment had no effect on CRP or MMP-9 plasma levels. 97 In contrast, treatment with glyburide has been associated with a decrease in CRP levels in 26 T2DM patients. 98 During a smaller study of 17 elderly diabetes patients treated with glimepiride, there was a significant decrease in TNFα levels. 99 Effects of SUs on adiponectin are conflicting, with one study showing no change in adiponectin levels after glimepiride administration in 84 patients, 97 whereas a smaller study involving 17 patients showing a reduction in plasma levels of adiponectin following glimepiride treatment. 99 It seems that the effects of SUs on inflammatory markers and adiponectin plasma levels in T2DM patients, if any, are weak.
A study of 81 T2DM patients has shown that glimepiride reduced PAI-1 levels, indicating that this drug facilitates fibrinolysis. 100 The mechanism for improvement in PAI-1 levels is unclear but may simply be due to a reduction in TG concentration. 101 SUs have been shown to restore ADP-induced aggregation of platelets to normal, 102 and these responses seem to be a class effect of these drugs. 103 However, the latter study was conducted ex vivo, on platelets from individuals with normoglycaemia, and it is unclear whether the same applies to platelets derived from subjects with diabetes. The effects of SUs on non-traditional risk factors are summarised in table 2.
Peroxisome proliferator-activated receptor (PPAR) agonists
Mode of action PPARs are ligand-activated transcription factors. There are three members, α, γ and β/δ, of which PPARγ is discussed in the current context because of its role in glucose and lipid metabolism. Upon activation, PPARγ forms a heterodimer with the nuclear retinoid receptor and binds to PPAR response elements in the promoter region of genes, thereby modulating expression of a large number of genes involved in glucose and lipid metabolism. Thiazolidinediones (TZDs) are compounds that activate PPARγ, resulting in a decrease in insulin resistance and consequent improvement in glu-cose metabolism. 104 In addition to their metabolic effects, TZDs directly modulate the atherothrombotic process by interfering with inflammatory and thrombotic processes, as detailed below.
Effects of thiazolidinediones on traditional risk factors
Many studies have shown that TZDs are effective at improving glycaemic control and ameliorating the insulin-resistant state. 104 The use of these agents has been associated with weight gain, due, at least partly, to increased fat tissue formation. However, the increase in adipose tissue is usually in the subcutaneous compartment and there may be a decrease in visceral fat, 105 resulting in a favourable net effect on adipose tissue distribution.
Both pioglitazone and rosiglitazone reduce plasma free fatty acids (FFA) and result in a modest increase in HDL levels with reduction of small, dense atherogenic LDL. [105] [106] However, these two agents differ in their effects on TG and LDL levels. 105, 107 A meta-analysis of 23 RCTs has shown that pioglitazone lowers TG and increases HDL, whilst having a neutral effect on LDL. On the other hand, rosiglitazone has been shown to increase HDL as well as TC and LDL, with a neutral effect on TG. 108 More recently, a prospective study compared three months' treatment with pioglitazone and rosiglitazone in respect to lipid profile in 400 and 402 diabetes patients, respectively. 109 Patients treated with pioglitazone showed a significant reduction in TG levels, whereas patients in the rosiglitazone group experienced an increase in plasma TG levels. Furthermore, pioglitazone was more effective than rosiglitazone at raising HDL levels over the short period of the study. However, patients in this study were not taking any lipid-lowering agents, in contrast to current common practice, making the general applicability of the results uncertain.
More recent work in 305 patients with diabetes who were already receiving statin treatment has shown that switching from rosiglitazone treatment to pioglitazone results in reduction in TC, LDL and TG levels with no effect on HDL, 110 suggesting that pioglitazone may offer greater cardiovascular protection compared with rosiglitazone. However, no outcome data are available comparing the two drugs and it remains unclear whether the 'friendlier' lipid profile associated with pioglitazone treatment translates clinically into better cardiovascular protection.
Several studies have conclusively shown that treatment with pioglitazone or rosiglitazone is associated with reductions in both SBP and DBP, compared with placebo or other OADs. 93, 111, 112 Furthermore, both rosiglitazone and pioglitazone have been shown to lower BP in patients with diabetes who have essential hypertension. 113, 114 The mechanism for the antihypertensive effects of these agents is probably related, at least in part, to improvement in endothelial function with consequent restoration of NO production, resulting in vasodilatation. Indeed, studies using flow-mediated dilatation, as a measure of endothelial dysfunction, have shown that TZDs can restore endothelial function, 115 thereby having a direct role in modulating vascular reactivity.
Monotherapy with glitazones has been associated with a reduction in urinary ACR in both normoalbuminuric and REVIEW microalbuminuric patients. 77, 94, 116, 117 Combination therapy with TZDs also reduces the ACR, regardless of whether TZDs are added to an SU or metformin. 77 This effect of TZDs suggests that these agents have renal protective properties. Moreover, as microalbuminuria is an indirect measure of endothelial dysfunction and is associated with increased cardiovascular mortality, a reduction in the ACR may indicate an improvement in endothelial function, with consequent reduction in cardiovascular risk. The effects of TZDs on traditional risk factors are summarised in table 1.
Effects of thiazolidinediones on non-traditional risk factors
In patients with diabetes, the use of glitazones is associated with a reduction in CRP levels, indicating a generalised antiinflammatory action of these drugs. 97, 109, 115, 118 Furthermore, these agents have been shown to reduce TNFα and increase adiponectin plasma levels. 119 A limited number of studies suggest that TZDs have antithrombotic properties, as these agents decrease platelet aggregation, inhibit vasoconstriction and delay intra-arterial thrombus formation in rats 120 by mechanisms that involve stimulation of NOS expression in the vessel wall and reduction of endothelin-1 and PAI-1 production. [120] [121] [122] [123] Human studies have shown that these agents not only reduce PAI-1 plasma levels but also result in a decrease in MMP-9, indicating that TZDs have a role in maintaining plaque stability. 97, 118, 124 Furthermore, rosiglitazone has been shown to reduce platelet activity in patients without diabetes but with coronary artery disease (CAD). 125 The mechanism for this remains unclear but is more likely to be due to an indirect effect (platelets do not express PPAR receptors), through improvement in endothelial function and restoration of NO production (a powerful physiological anti-platelet agent). Neither pioglitazone nor rosiglitazone seems to have an effect on tPA or fibrinogen levels in patients with diabetes. 124 The effects of TZDs on non-traditional risk factors are summarised in table 2.
Alpha glucosidase inhibitors
Mode of action This group of drugs (acarbose, miglitol, voglibose) acts locally in the intestine by inhibiting α-glucosidases, resulting in delayed digestion of starch and sucrose. This in turn leads to flattening of the postprandial glucose excursions and delayed carbohydrate absorption. 126 Effects of alpha glucosidase inhibitors on traditional risk factors Although these agents have been consistently shown to improve glycaemic control, they seem to have a limited effect on the lipid profile, with some studies showing a minor reduction in TC and TG whilst the majority demonstrate no effect. 76 Alpha glucosidase inhibitors have no significant effect on BP or microalbuminuria in patients with diabetes. 94, 127, 128 Effects of alpha glucosidase inhibitors on non-traditional risk factors No human studies have been conducted in this area, perhaps because the local mode of action of these agents makes them unlikely to have significant systemic effects, other than those related to their glucose-lowering properties. Investigations in animals have shown that acarbose treatment can reduce both acute and chronic platelet activation in Zucker rats; such an effect may have contributed to the protection from cardiovascular events documented in the Study to Prevent Non-Insulin Dependent Diabetes Mellitus (STOP-NIDDM). [129] [130] [131] However, a recent systematic review has failed to show that treatment with α-glucosidase inhibitors reduces mortality or morbidity in patients with diabetes. 132 These agents are rarely used for the treatment of diabetes in the UK, mainly due to their gastrointestinal side effects and their modest effect on glycaemic control. This class of agents is, however, widely used in China and other developing countries. The effects of α-glucosidase inhibitors on traditional and non-traditional risk factors are summarised in tables 1 and 2, respectively.
Oral agents and clinical cardiovascular disease markers
Carotid intima-media thickness (IMT) has been used as a surrogate marker for cardiovascular risk, and a thick IMT correlates with future cardiovascular events. 133 Measurement of IMT has been used as a non-invasive technique to estimate atherosclerotic load. In a two-year, open-label study involving 82 Japanese T2DM patients, treatment with metformin in 36 patients has been shown to attenuate the progression of carotid IMT, indicating a direct role for this agent in modulating the atherosclerotic process. 134 In a study of 197 T2DM patients, pioglitazone has been shown to reduce IMT compared with glimepiride as early as 12 weeks after starting treatment, with sustained improvement at 24 weeks, an effect that was independent of glycaemic control. 135 In a study involving 92 non-diabetic individuals with CAD, treatment with rosiglitazone was associated with a significant reduction of IMT at 48 weeks compared with placebo-treated subjects. 136 TZDs also have an effect on the coronary arteries. A recent study in 83 T2DM patients with CAD requiring angioplasty showed that rosiglitazone treatment significantly reduced the rate of stent restenosis at six months compared with placebo, as assessed by coronary angiography. 137 A more recent study involving 54 T2DM patients reported similar findings using pioglitazone, suggesting a mechanism of action that may be related to a reduction in leptin levels and improvement in endothelial function. 138 Moreover, pioglitazone has been shown to reduce coronary artery stent restenosis in CAD patients with no history of diabetes, as assessed by intravascular ultrasound, 139 further suggesting direct anti-atherosclerotic properties for TZDs. The exact mechanisms for these effects of TZDs are not entirely clear and are likely to involve multiple pathways, with inhibition of neointimal tissue proliferation playing a central role. 139, 140 A reduction in arterial distensibility is a marker of atherosclerotic load, and aortic stiffness has been shown to be associated with future cardiovascular events. 141 Therefore, atherosclerotic load can be measured indirectly by analysing pulse wave velocity in an artery. Treatment with pioglitazone and rosiglitazone has been associated with increased arteri-al distensibility, suggesting a reduction in atherosclerotic load, 142, 143 and therefore that these agents may reverse, or at least halt, the progression of atherosclerosis.
Oral agents and cardiovascular outcome studies
The UKPDS reported that treatment of overweight T2DM patients with metformin was associated with a 39% reduction in MI, which compares favourably with the effects of other cardioprotective agents such as angiotensin-converting enzyme inhibitors and statins. 71 The mechanisms for the protective effects of metformin are probably multifactorial, including modulation of the inflammatory atherosclerotic process, interference with thrombus formation and the beneficial effects on metabolic parameters detailed above. The UKPDS, in which metformin reduced MI and diabetes-related death, has led to recommendations that metformin should be the first-line agent of choice in overweight patients with T2DM.
There is no indication that the SUs have a significant cardioprotective role as data from the UKPDS have shown that SU treatment does not protect from cardiovascular events. 25 Indeed, some studies suggest that treatment with SUs increases cardiovascular risk in patients with diabetes. The University Group Diabetes Project (UGDP), conducted almost 40 years ago, showed an increased risk of cardiovascular events in subjects treated with an SU. 144 Furthermore, a recent retrospective analysis of almost 5,800 patients with T2DM has shown that SU treatment (n=4,258 subjects) is associated with increased cardiovascular mortality, with a hazard ratio ranging from 2.1 for first-generation to 1.3 for second-generation SUs. In the same study there was a slight, albeit non-significant, decrease in CV mortality with metformin use (n=1,537 subjects; hazard ratio=0.8).
Recent evidence suggests that the increased risk of mortality with SU treatment is due to impaired cardiac ischaemic preconditioning. 145 This effect is a particular concern with glibenclamide but it does not seem to be a feature of gliclazide at therapeutic concentrations because gliclazide lacks a benzamido group, so it does not bind to SUR2A/Kir6.2. 146 The above studies indicate that the SUs do not offer protection from CVD and may, where they have a benzamido binding property, increase the risk of cardiovascular events.
The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) is the only outcome study using a TZD, pioglitazone, in T2DM patients to have reported to date. It was a randomised, double-blind, placebocontrolled study of more than 5,000 T2DM patients with established macrovascular complications. 147 Patients were randomised to receive pioglitazone or placebo in addition to their existing medications. Almost all patients were on cardiovascular medications but only half were on lipid-lowering treatment. The primary end point of the study was the first occurrence of any of the events in the following composite: all-cause mortality, non-fatal MI (including silent MI), stroke, major leg amputation, acute coronary syndrome, cardiac or leg revascularisation. In addition, the study had a predefined secondary end point, which was the composite of all-cause mortality, non-fatal MI (excluding silent MI) and stroke. Over 3.4 years, there was a non-significant reduction of 10% in the primary composite end point and a significant reduction of 16% in the composite secondary end point. Post-hoc analysis of the patients with a previous MI has shown that time to the composite cardiac end point was reduced by 19%, which was statistically significant (p=0.03), as was the risk reduction of recurrent MI and acute coronary syndromes (risk reduction of 28% and 37%, respectively). 148 Unfortunately, this study has created a lot of controversy and has somewhat polarised opinions with regard to the role of TZDs in cardiovascular protection. [149] [150] [151] [152] [153] The failure of the primary end point to reach statistical significance has led some to consider PROactive as a negative study and to conclude that the TZDs have no cardiovascular protective effect. This purist view highlights the gap between the design and conduct of modern trials and their interpretation. It is far easier to criticise a trial than to carry it through, and similar protestations were raised after the metformin UKPDS results. The effects of TZDs on cardiovascular surrogates suggest that any beneficial effect would be seen in acute coronary syndromes and other conditions with similar pathophysiology. Justified criticisms of study design should not be allowed to mask the fact that this is exactly the group in whom the benefit appears to be seen.
Of equal importance is the question of whether the treatment is causing unacceptable levels of side effects. In PROactive, there were more cases of reported heart failure associated with the use of pioglitazone. This has led to the suggestion that the study would not have shown any benefits of TZDs if the heart failure data had been included in the secondary end point. 152 However, heart failure was not adjudicated in this study and the numbers of deaths from heart failure were similar in the two groups, suggesting that some cases were misdiagnosed due to the presence of peripheral oedema, a recognised side effect of TZD treatment. An additional finding was that pioglitazone treatment was associated with a 50% reduction in progression to permanent insulin use (p<0.0001), sparing T2DM patients the need for the introduction of early insulin therapy.
The Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes trial (RECORD) is another outcome study, a six-year, randomised, open-label study in T2DM patients with inadequate blood glucose control (HbA 1C 7.1-9.0%) on metformin or sulphonylurea alone. Participants are randomised to add-on rosiglitazone, metformin or sulphonylurea, with dose titration to a target HbA 1C of 7.0%. The primary end point is the time to reach the combined end point of cardiovascular death and/or hospitalisation. 154 The study is expected to report in 2009.
Oral agents and diabetes prevention
As diabetes and cardiovascular disease co-exist due to risk factor clustering, diabetes prevention will result in protection from cardiovascular disease. The role of OADs in diabetes prevention has been investigated in a number of studies. The diabetes prevention programme (DPP) has shown that treatment with metformin in individuals with impaired glucose tolerance results in a 31% reduction in the development of diabetes over a period of 2.8 years. 155 However, it is worth REVIEW noting that intensive life-style intervention was more effective at preventing diabetes in this study (58% reduction), emphasising the role of diet and exercise.
Although it was terminated early due to the withdrawal of troglitazone from the market, the TRoglitazone In the Prevention Of Diabetes mellitus trial (TRIPOD) has shown that treatment with TZD in Hispanic non-diabetic women with a history of gestational diabetes reduced the risk of developing diabetes by 56% over 30 months, indicating a role for this class of drugs in diabetes prevention. 156 Women who did not develop diabetes in the TRIPOD study were subsequently enrolled into an open-label observational study investigating the effect of pioglitazone on beta-cell function in the Pioglitazone In the Prevention Of Diabetes trial (PIPOD). This study demonstrated that pioglitazone treatment for three years is associated with a relatively low rate of diabetes in women with a history of gestational diabetes, further supporting a role for TZDs in modifying the progression to diabetes in high-risk subjects. 157 STOP-NIDDM has demonstrated that acarbose treatment of subjects with impaired glucose tolerance reduced progression to diabetes by 25% over 3.3 years. However, the discontinuation rate of acarbose due to gastrointestinal side effects was high at 48%, which limited use of this drug. 158 The Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial assessed the role of ramipril and rosiglitazone in the prevention of diabetes and CVD in subjects with impaired glucose tolerance. Rosiglitazone (but not ramipril) reduced incident diabetes by > 60% over three years. 159 ACTos Now for prevention of diabetes (ACT NOW) is investigating the effect of pioglitazone on the development of diabetes in subjects with impaired glucose tolerance. 160 This will report within the next two years. 160 The Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial is currently investigating the role of the insulin secretagogue nateglinide, with or without valsartan, in the prevention of diabetes and CVD in high-risk subjects. 161 
Conclusion
Prevention of macrovascular disease in diabetes involves a multidisciplinary approach directed at modulating a number of risk factors. Glucose-lowering therapy has only a limited role in CVD prevention in diabetes; an ideal oral agent should have the ability to modulate some, or preferably all, of the known modifiable cardiovascular risk factors associated with insulin resistance and T2DM. The most widely used oral agents in the UK include metformin, insulin secretagogues (mainly SUs) and TZDs. Metformin lowers blood glucose and has beneficial effects on a number of risk factors, including weight, inflammatory markers and coagulation factors, with minor positive effects on lipids and BP. The use of metformin has been associated with a reduction in cardiovascular events in overweight type 2 diabetes patients. SUs are effective at reducing blood glucose and may have minor effects on other risk factors including BP, lipids and microalbuminuria, but studies have thus far failed to show any effect of these agents on reducing cardiovascular events or mortality. TZDs have a wide spectrum of activity and seem to be able to modulate many CV risk factors through amelioration of insulin resistance and improvement of hyperglycaemia, in addition to providing a beneficial effect on lipid profile, BP, microalbuminuria, inflammation and coagulation. The recent PROactive trial has reported a reduction in all-cause mortality and cardiovascular events with pioglitazone use in high-risk diabetes patients. However, this class of drugs may potentially predispose to heart failure, and should be used with caution in individuals with abnormal cardiac function.
In summary, current evidence suggests that amongst the OADs, metformin and the TZDs have cardiovascular protective activities and therefore these should be considered as first-line agents in patients with T2DM.
